Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Abbisko Therapeutics
Biotech
Eli Lilly reunites with Abbisko in $1.9B, multitarget R&D pact
Lilly has expanded its ties to Abbisko, committing up to $1.9 billion to get the Chinese biotech to apply its capabilities to multiple targets.
Nick Paul Taylor
Jun 24, 2026 7:47am
Merck KGaA pays $85M for global rights to Abbisko's tumor drug
Apr 1, 2025 7:40am
Merck KGaA tacks on Abbisko’s joint tumor med for $70M upfront
Dec 4, 2023 10:26am
Lilly extends JPM collab theme in $1B Evotec pact, Abbisko deal
Jan 18, 2022 11:30am
Chinese I-O biotech Abbisko raises $28M in first-round funding
Feb 8, 2017 8:53am
